Invivosciences
US-based company offering phenotypic screening for innovative drug discovery and repositioning.
Founded
2001US-based company offering phenotypic screening for innovative drug discovery and repositioning.
invivosciences.comCrawled Oct 16, 2026
InvivoSciences planned to attend and present at the Bio 2020 Annual Meeting in San Diego, California, June 8–11, 2020. The page says the conference had not been cancelled.
Career Opportunities aannac@invivosciences.com+1-608-628-8035Tetsuro Wakatsukitetsuro@invivosciences.com+1-608-566-6162
InvivoSciences’ management team has diverse experience and education and understanding of the biotech and pharmaceutical industries.
InvivoSciences launched in 2001 in St. Louis, Missouri, with technology licensed from Washington University in St. Louis. In 2005, founders Tetsuro Wakatsuki, Ayla Annac, and Elliot Elson moved the company to Wisconsin.
The page lists Wisconsin Small Business Innovation Awards for Outstanding Achievements and Edison Awards.
Pharmaceutical companies face pressure to improve drug development productivity amid near-empty product pipelines, high demand and looming patent expirations; weak IPO markets have made biotech companies acquisition targets.
InvivoSciences’ research, products, and technological advancements have been published in more than a dozen scientific journals over the past 20-plus years.
InvivioSciences, Inc. lists an office at 510 Charmany Drive, Suite 59, Madison, WI 53719, with phone number +1-608-713-0149 and email info@invivosciences.com.
InvivoSciences, Inc. is a precision medicine company that personalizes drug development using patient-derived and gene-edited human samples, including an automated, scalable, functional 3D engineered micro-human heart tissue platform.